CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success

• click to rate

  Posted by Two Blokes May 22, 2025 - Filed in Stock - 5 views
  
  CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.